Carisma Therapeutics

Company snapshot

Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucia

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Carisma Therapeutics. Not investment advice.

• What is Carisma Therapeutics?

  Carisma Therapeutics is a pharma organization headquartered in Philadelphia, USA. It trades on NYSE under ticker CARM. Primary therapeutic focus areas include HER2-positive. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 2 patent record(s) to this entity from

• Is Carisma Therapeutics publicly traded?

  Yes. Carisma Therapeutics is listed with ticker CARM on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Carisma Therapeutics develop or market?

  We link 1 drug profile(s) where Carisma Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/carisma-therapeutics#company-drugs.

• What are the latest developments for Carisma Therapeutics?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Carisma Therapeutics focus on?

  Carisma Therapeutics focuses on HER2-positive based on our analysis of their pipeline programs and drug development activities.